ReviewInternational journal of medical microbiology : IJMM2012
Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.
Review in International journal of medical microbiology : IJMM, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it, 247 citations in OpenAlex.
- Prioritization of Critical Factors for Surveillance of the Dissemination of Antibiotic Resistance inInternational journal of molecular sciences · 2023Pooled it
- Structure-based classification of bacterial chitooligosaccharide-specific outer membrane porins (ChiPs).The Journal of biological chemistry · 2026Article
- Molecular determinants associated with resistance to imipenem and imipenem-relebactam in clinical Pseudomonas aeruginosa isolates.BMC genomics · 2026Article
- Characterization of two exoUBMC microbiology · 2026Article
- Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.npj antimicrobials and resistance · 2026Article
- Experimental evolution reveals adaptive pathways to reduced antibiotic susceptibility inMicrobiology (Reading, England) · 2026Article
- Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- TXA11114: Discovery of anAntibiotics (Basel, Switzerland) · 2026Article
- Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics.MicrobiologyOpen · 2026Review
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Within-host adaptation mutations associated with persistent colonization ofFrontiers in cellular and infection microbiology · 2026Article
- Whole-genome sequencing reveals molecular characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Emergence of ST1076 as a dominant high-risk clone carryingFrontiers in microbiology · 2026Article
- Understanding Drug Permeability inLife (Basel, Switzerland) · 2025Review
- Article
- A novel homoarginine-containing cyclic peptide pioamide with selective antipseudomonal activity isolated from the nematode symbiontApplied and environmental microbiology · 2025Article
- Minimal gene signatures enable high-accuracy prediction of antibiotic resistance in Pseudomonas aeruginosa.NPJ systems biology and applications · 2025Article
- Molecular characterization of metallo-beta-lactamase producers among carbapenem-resistant Pseudomonas aeruginosa from clinical samples in a tertiary care hospital, Lucknow, India.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Bioinspired Nanoplatforms: Polydopamine and Exosomes for Targeted Antimicrobial Therapy.Polymers · 2025Review
- A biofilm-targeting lipo-peptoid to treatBiofilm · 2025Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen isolated from patients with nosocomial infections. Due to its intrinsic and acquired antimicrobial resistance, limited classes of antibiotics can be used for the treatment of infection with P. aeruginosa. Of these, the carbapenems are very important; however, the occurrence of carbapenem-resistant strains is gradually increasing over time. Deficiency of the outer membrane protein OprD confers P. aeruginosa a basal level of resistance to carbapenems, especially to imipenem. Functional studies have revealed that loops 2 and 3 in the OprD protein contain the entrance and/or binding sites for imipenem. Therefore, any mutation in loop 2 and/or loop 3 that causes conformational changes could result in carbapenem resistance. OprD is also a common channel for some amino acids and peptides, and competition with carbapenems through the channel may also occur. Furthermore, OprD is a highly regulated protein at transcriptional and post-transcriptional levels by some metals, small bioactive molecules, amino acids, and efflux pump regulators. Because of its hypermutability and highly regulated properties, OprD is thought to be the most prevalent mechanism for carbapenem resistance in P. aeruginosa. Developing new strategies to combat infection with carbapenem-resistant P. aeruginosa lacking OprD is an ongoing challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.